114 related articles for article (PubMed ID: 31704844)
1. Effect of Tissue Transglutaminase on Steroid Resistance in T-Cell Acute Lymphoblastic Leukemia.
Jung HJ; Han EH; Jang IK; Yoon SH; Park JE
Anticancer Res; 2019 Nov; 39(11):6165-6173. PubMed ID: 31704844
[TBL] [Abstract][Full Text] [Related]
2. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
Jung HJ; Chen Z; Wang M; Fayad L; Romaguera J; Kwak LW; McCarty N
Blood; 2012 Mar; 119(11):2568-78. PubMed ID: 22294726
[TBL] [Abstract][Full Text] [Related]
3. Tissue transglutaminase-mediated chemoresistance in cancer cells.
Verma A; Mehta K
Drug Resist Updat; 2007; 10(4-5):144-51. PubMed ID: 17662645
[TBL] [Abstract][Full Text] [Related]
4. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
5. Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target.
Agnihotri N; Mehta K
Amino Acids; 2017 Mar; 49(3):425-439. PubMed ID: 27562794
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival.
Fisher ML; Keillor JW; Xu W; Eckert RL; Kerr C
Mol Cancer Res; 2015 Jul; 13(7):1083-94. PubMed ID: 25934691
[TBL] [Abstract][Full Text] [Related]
7. Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor.
Han AL; Kumar S; Fok JY; Tyagi AK; Mehta K
Eur J Cancer; 2014 Jun; 50(9):1685-96. PubMed ID: 24656569
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Transglutaminase 2 activity increases cisplatin cytotoxicity in a model of human hepatocarcinoma chemotherapy.
Meshram DD; Pike CVS; Coussons PJ
Eur J Pharmacol; 2017 Nov; 815():332-342. PubMed ID: 28943101
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
[TBL] [Abstract][Full Text] [Related]
10. Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype.
Brown KD
Breast Cancer Res Treat; 2013 Jan; 137(2):329-36. PubMed ID: 23224146
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminase 2 modulation of NF-κB signaling in astrocytes is independent of its ability to mediate astrocytic viability in ischemic injury.
Feola J; Barton A; Akbar A; Keillor J; Johnson GVW
Brain Res; 2017 Aug; 1668():1-11. PubMed ID: 28522262
[TBL] [Abstract][Full Text] [Related]
12. The complex role of transglutaminase 2 in glioblastoma proliferation.
Gundemir S; Monteagudo A; Akbar A; Keillor JW; Johnson GVW
Neuro Oncol; 2017 Feb; 19(2):208-218. PubMed ID: 27591334
[TBL] [Abstract][Full Text] [Related]
13. Transglutaminase 2 regulates osteoclast differentiation via a Blimp1-dependent pathway.
Kim WS; Kim H; Jeong EM; Kim HJ; Lee ZH; Kim IG; Kim HH
Sci Rep; 2017 Sep; 7(1):10626. PubMed ID: 28878266
[TBL] [Abstract][Full Text] [Related]
14. Transglutaminase 2 and NF-kappaB interplay during NGF-induced differentiation of neuroblastoma cells.
Condello S; Caccamo D; Currò M; Ferlazzo N; Parisi G; Ientile R
Brain Res; 2008 May; 1207():1-8. PubMed ID: 18374307
[TBL] [Abstract][Full Text] [Related]
15. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
van der Zwet JCG; Buijs-Gladdines JGCAM; Cordo' V; Debets DO; Smits WK; Chen Z; Dylus J; Zaman GJR; Altelaar M; Oshima K; Bornhauser B; Bourquin JP; Cools J; Ferrando AA; Vormoor J; Pieters R; Vormoor B; Meijerink JPP
Leukemia; 2021 Dec; 35(12):3394-3405. PubMed ID: 34007050
[TBL] [Abstract][Full Text] [Related]
16. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation.
Kim DS; Park SS; Nam BH; Kim IH; Kim SY
Cancer Res; 2006 Nov; 66(22):10936-43. PubMed ID: 17108131
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer.
Mehta K; Fok J; Miller FR; Koul D; Sahin AA
Clin Cancer Res; 2004 Dec; 10(23):8068-76. PubMed ID: 15585642
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of transglutaminase 2 accelerates the erythroid differentiation of human chronic myelogenous leukemia K562 cell line through PI3K/Akt signaling pathway.
Kang SK; Lee JY; Chung TW; Kim CH
FEBS Lett; 2004 Nov; 577(3):361-6. PubMed ID: 15556610
[TBL] [Abstract][Full Text] [Related]
19. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
[TBL] [Abstract][Full Text] [Related]
20. Implications of tissue transglutaminase expression in malignant melanoma.
Fok JY; Ekmekcioglu S; Mehta K
Mol Cancer Ther; 2006 Jun; 5(6):1493-503. PubMed ID: 16818508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
